Fig. 7: Combination treatment of oseltamivir, linezolid and disulfiram can inhibit macrophage pyroptosis in the lung and alleviate pneumonia. | Cell Death Discovery

Fig. 7: Combination treatment of oseltamivir, linezolid and disulfiram can inhibit macrophage pyroptosis in the lung and alleviate pneumonia.

From: Excessive pyroptosis mediates the exacerbation of pneumonia caused by low-lethality influenza virus and secondary MRSA co-infection

Fig. 7: Combination treatment of oseltamivir, linezolid and disulfiram can inhibit macrophage pyroptosis in the lung and alleviate pneumonia.The alternative text for this image may have been generated using AI.

A Experimental scheme for assessing the combination treatment of oseltamivir, linezolid and disulfiram. B Gross pathological changes of lung tissues were evaluated. C Lung index was calculated in different groups (n = 6). Lung index = lung weight of mice (mg)/body weight of mice (g). D mRNA levels of IL-1β, CXCL-2 and TNF-α were measured by qRT-PCR (n = 4). Data are normalized to β-actin and presented as fold of gene expression in the infected groups compared to the control. E Representative pathological images (Scale bars: above 200 μm; below 100 μm) of lung tissue in different groups. Stain areas of images were calculated using image j and then normalized to the average area of the control group (n = 3). F Immunofluorescence staining of F4/80 (red) and GSDMD (green), the scale bars are 20 μm (left) or 10 μm (right). Data are mean ± standard error of the mean (*p < 0.05; **p < 0.01; ***p < 0.001). IAV Influenza virus, MRSA methicillin-resistant S. aureus, Ost oseltamivir, Lzd linezolid, Dsf disulfiram.

Back to article page